Global Cancer Anorexia-Cachexia Syndrome Disease Clinical Trials Review, H2 2020 Edition Featuring 10 Key Players & Their Respective Trials – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cancer Anorexia-Cachexia Syndrome Disease – Global Clinical Trials Review, H2, 2020” clinical trials has been added to ResearchAndMarkets.com’s offering.

“Cancer Anorexia-Cachexia Syndrome Disease – Global Clinical Trials Review, H2, 2020” provides an overview of Cancer Anorexia-Cachexia Syndrome Clinical trials scenario.

This report provides top line data relating to the clinical trials on Cancer Anorexia-Cachexia Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Reasons to Buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

Report Guidance

• Clinical Trials Report Coverage

Clinical Trials by Region

• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Countries Contributing to Clinical Trials in Middle East and Africa
• Top Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Cancer Anorexia-Cachexia Syndrome to Oncology Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Cancer Anorexia-Cachexia Syndrome to Oncology Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

• In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

• Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

• Prominent Sponsors

Top Companies Participating in Cancer Anorexia-Cachexia Syndrome Therapeutics Clinical Trials

Prominent Drugs

• Clinical Trial Profile Snapshots

Appendix

Companies Mentioned

• Helsinn Group
• Oncternal Therapeutics
• Aeterna Zentaris Inc
• Pfizer Inc
• Ono Pharmaceutical Co Ltd
• Ark Therapeutics Ltd
• AstraZeneca Plc
• Endo International Plc
• IQVIA Holdings Inc
• Medpace Holdings Inc

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/mryc8a

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900